Country: Ástralía
Tungumál: enska
Heimild: APVMA (Australian Pesticides and Veterinary Medicines Authority)
CIMICOXIB
VETOQUINOL AUSTRALIA PTY LTD
ORAL BOLUS, CHEWABLE
CIMICOXIB ANTI-INFLAMMATORY Active 30.0 mg/Tb
144 tablets; 32 tablets; 8 tablets
VM - Veterinary Medicine
ANALGESIC+MUSCULOSKELETAL
Poison schedule: 4; Withholding period: ; Host/pest details: DOG: [ANALGESIC, MUSCOSKELETAL DISCOMFORT, MUSCULOSKELETAL CONDITIONS, ORTHOPAEDIC - INFLAMATION]
Registered
2023-07-01
CIMALGEX 30 mg CHEWABLE TABLETS FOR DOGS 84021/109517 Product Name: APVMA Approval No: Label Name: CIMALGEX 30 mg CHEWABLE TABLETS FOR DOGS Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY READ SAFETY DIRECTIONS BEFORE OPENING OR USING Constituent Statements: Each tablet contains 30 mg Cimicoxib Claims: For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopaedic or soft tissue surgery, in dogs. Net Contents: 8 tablets 32 tablets 144 tablets Directions for Use: Restraints: Contraindications: This product should not be used in dogs suffering from gastrointestinal disorders or haemorrhagic disorders. This product should not be used in dogs exhibiting previous hypersensitivity to cimicoxib. This product is contraindicated for use in any animals which are dehydrated, hypovolaemic or hypotensive, as it may increase the risk of renal toxicity. Precautions: The safety of CIMALGEX in dogs less than 10 weeks of age or in breeding, pregnant or lactating animals has not been established. Although no data are available in dogs, studies with laboratory animals have shown effects on fertility and foetal development. RLP APPROVED Since the safety of cimicoxib has not been adequately demonstrated in young animals, careful monitoring is advised during the treatment of young dogs aged less than 6 months. Avoid administration concurrently with corticosteroids or other non-steroidal anti- inflammatory drugs (NSAIDs). Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects. A treatment-free period, taking into account the pharmacokinetic properties of such substances, should be observed before initiation of treatment with CIMALGEX CHEWABLE TABLETS FOR DOGS. Use in animals suffering from impaired cardiac or hepatic function may involve additional risk. If such use cannot be avoided, these animals require careful veterinary monitoring. Use CIMALGEX CHEWABLE TAB Lestu allt skjalið